Skip to content

Released Aug 7, 2023, after the close

10-Q filed Aug 7, 2023, 38 days after period end · 0001628280-23-027772

Q2 2023 · 10-Q
Revenue$0.00no prior Q2 2022 on fileno prior Q1 2023 on file
Net Income-$42.39MN/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.47N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$45,257,000N/M
Operating Cash Flowderived-$40,821,000N/M
Free Cash Flowderived-$42,797,000N/M

What the release said

The release

Same quarter

MetricQ2 2023Q2 2022Q2 2021
Revenue$0.00——
Net Income-$42.39M-$29.35M$616.00K
EPS Diluted-$0.47-$1.76—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR